🎉 M&A multiples are live!
Check it out!

ImmunityBio Valuation Multiples

Discover revenue and EBITDA valuation multiples for ImmunityBio and similar public comparables like Benevolent AI, Julphar, and Galapagos.

ImmunityBio Overview

About ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.


Founded

2014

HQ

United States of America
Employees

680

Website

immunitybio.com

Financials

LTM Revenue $40.8M

LTM EBITDA n/a

EV

$2.9B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

ImmunityBio Financials

ImmunityBio has a last 12-month revenue of $40.8M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, ImmunityBio achieved revenue of $14.7M and an EBITDA of -$264M.

ImmunityBio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See ImmunityBio valuation multiples based on analyst estimates

ImmunityBio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.6M $14.7M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$436M -$264M XXX XXX XXX
EBITDA Margin -70126% -1793% XXX XXX XXX
Net Profit -$417M -$583M XXX XXX XXX
Net Margin -66972% -3955% XXX XXX XXX
Net Debt $569M $416M XXX XXX XXX

Financial data powered by Morningstar, Inc.

ImmunityBio Stock Performance

As of April 15, 2025, ImmunityBio's stock price is $3.

ImmunityBio has current market cap of $2.6B, and EV of $2.9B.

See ImmunityBio trading valuation data

ImmunityBio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.9B $2.6B XXX XXX XXX XXX $-0.62

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

ImmunityBio Valuation Multiples

As of April 15, 2025, ImmunityBio has market cap of $2.6B and EV of $2.9B.

ImmunityBio's trades at 71.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate ImmunityBio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for ImmunityBio and 10K+ public comps

ImmunityBio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.9B XXX XXX XXX
EV/Revenue 197.0x XXX XXX XXX
EV/EBITDA -11.0x XXX XXX XXX
P/E -6.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -7.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ImmunityBio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

ImmunityBio Valuation Multiples

ImmunityBio's NTM/LTM revenue growth is 294%

ImmunityBio's revenue per employee for the last fiscal year averaged $22K, while opex per employee averaged $0.5M for the same period.

Over next 12 months, ImmunityBio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate ImmunityBio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for ImmunityBio and other 10K+ public comps

ImmunityBio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 2271% XXX XXX XXX XXX
EBITDA Margin -1793% XXX XXX XXX XXX
EBITDA Growth -39% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -1499% XXX XXX XXX XXX
Revenue per Employee $22K XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 1290% XXX XXX XXX XXX
Opex to Revenue 2434% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

ImmunityBio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

ImmunityBio M&A and Investment Activity

ImmunityBio acquired  XXX companies to date.

Last acquisition by ImmunityBio was  XXXXXXXX, XXXXX XXXXX XXXXXX . ImmunityBio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by ImmunityBio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About ImmunityBio

When was ImmunityBio founded? ImmunityBio was founded in 2014.
Where is ImmunityBio headquartered? ImmunityBio is headquartered in United States of America.
How many employees does ImmunityBio have? As of today, ImmunityBio has 680 employees.
Who is the CEO of ImmunityBio? ImmunityBio's CEO is Mr. Richard Adcock.
Is ImmunityBio publicy listed? Yes, ImmunityBio is a public company listed on NAS.
What is the stock symbol of ImmunityBio? ImmunityBio trades under IBRX ticker.
When did ImmunityBio go public? ImmunityBio went public in 2021.
Who are competitors of ImmunityBio? Similar companies to ImmunityBio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of ImmunityBio? ImmunityBio's current market cap is $2.6B
What is the current revenue of ImmunityBio? ImmunityBio's last 12-month revenue is $40.8M.
What is the current EV/Revenue multiple of ImmunityBio? Current revenue multiple of ImmunityBio is 71.2x.
What is the current revenue growth of ImmunityBio? ImmunityBio revenue growth between 2023 and 2024 was 2271%.
Is ImmunityBio profitable? Yes, ImmunityBio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.